Literature DB >> 26281628

Reply: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Helen A Mintz-Hittner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 26281628      PMCID： PMC4545290          DOI： 10.1097/iae.0b013e31819a98b9

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  4 in total

1.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Authors:  Shigeru Honda; Hiroaki Hirabayashi; Yasutomo Tsukahara; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-03-05       Impact factor: 3.117

2.  Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.

Authors:  Lingkun Kong; Helen A Mintz-Hittner; Rebecca L Penland; Francis L Kretzer; Patricia Chévez-Barrios
Journal:  Arch Ophthalmol       Date:  2008-08

3.  Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

Authors:  Kenan Sonmez; Kimberly A Drenser; Antonio Capone; Michael T Trese
Journal:  Ophthalmology       Date:  2007-11-26       Impact factor: 12.079

4.  Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity.

Authors:  H A Mintz-Hittner; F L Kretzer
Journal:  Ophthalmology       Date:  1994-03       Impact factor: 12.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.